Serum human epididymis protein 4 vs. carbohydrate antigen 125 for ovarian cancer diagnosis: A systematic review

Simona Ferraro, Federica Braga, Monica Lanzoni, Patrizia Boracchi, Elia Mario Biganzoli, Mauro Panteghini

Research output: Contribution to journalArticle

Abstract

Human epididymis protein 4 (HE4) measurements in serum have been proposed for improving the specificity of laboratory identification of ovarian cancer (OC). This study sought to critically revise the available literature on the comparison between the diagnostic accuracy of HE4 and carbohydrate antigen 125 (CA-125) to provide evidence of HE4 additional clinical value. Literature search was undertaken on electronic databases and references from retrieved articles, and articles analyzed according to predefined criteria. Meta-analyses for HE4 and CA-125 biomarkers with odds ratio (OR), diagnostic sensitivity, specificity, positive (LR+) and negative (LR-) likelihood ratios as effect sizes were performed. Sixteen articles were originally included in meta-analyses, but two for HE4 and one for CA-125 were eliminated as outliers. Furthermore, for HE4 a publication bias was detected. ORs for both HE4 (37.2, 95% CI: 19.0-72.7, adjusted for publication bias) and CA-125 (15.4, 95% CI: 10.4-22.8) were significant, although in a heterogeneous set of studies (P

Original languageEnglish
Pages (from-to)179-189
Number of pages11
JournalBiochimica Clinica
Volume37
Issue number3
Publication statusPublished - Jun 2013

Fingerprint

Epididymis
Ovarian Neoplasms
Carbohydrates
Antigens
Serum
Proteins
Publication Bias
Meta-Analysis
Biomarkers
Odds Ratio
Databases
Sensitivity and Specificity

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical
  • Medical Laboratory Technology

Cite this

Serum human epididymis protein 4 vs. carbohydrate antigen 125 for ovarian cancer diagnosis : A systematic review. / Ferraro, Simona; Braga, Federica; Lanzoni, Monica; Boracchi, Patrizia; Biganzoli, Elia Mario; Panteghini, Mauro.

In: Biochimica Clinica, Vol. 37, No. 3, 06.2013, p. 179-189.

Research output: Contribution to journalArticle

Ferraro, S, Braga, F, Lanzoni, M, Boracchi, P, Biganzoli, EM & Panteghini, M 2013, 'Serum human epididymis protein 4 vs. carbohydrate antigen 125 for ovarian cancer diagnosis: A systematic review', Biochimica Clinica, vol. 37, no. 3, pp. 179-189.
Ferraro, Simona ; Braga, Federica ; Lanzoni, Monica ; Boracchi, Patrizia ; Biganzoli, Elia Mario ; Panteghini, Mauro. / Serum human epididymis protein 4 vs. carbohydrate antigen 125 for ovarian cancer diagnosis : A systematic review. In: Biochimica Clinica. 2013 ; Vol. 37, No. 3. pp. 179-189.
@article{cf33c94f69c8405c8916be8346db9400,
title = "Serum human epididymis protein 4 vs. carbohydrate antigen 125 for ovarian cancer diagnosis: A systematic review",
abstract = "Human epididymis protein 4 (HE4) measurements in serum have been proposed for improving the specificity of laboratory identification of ovarian cancer (OC). This study sought to critically revise the available literature on the comparison between the diagnostic accuracy of HE4 and carbohydrate antigen 125 (CA-125) to provide evidence of HE4 additional clinical value. Literature search was undertaken on electronic databases and references from retrieved articles, and articles analyzed according to predefined criteria. Meta-analyses for HE4 and CA-125 biomarkers with odds ratio (OR), diagnostic sensitivity, specificity, positive (LR+) and negative (LR-) likelihood ratios as effect sizes were performed. Sixteen articles were originally included in meta-analyses, but two for HE4 and one for CA-125 were eliminated as outliers. Furthermore, for HE4 a publication bias was detected. ORs for both HE4 (37.2, 95{\%} CI: 19.0-72.7, adjusted for publication bias) and CA-125 (15.4, 95{\%} CI: 10.4-22.8) were significant, although in a heterogeneous set of studies (P",
author = "Simona Ferraro and Federica Braga and Monica Lanzoni and Patrizia Boracchi and Biganzoli, {Elia Mario} and Mauro Panteghini",
year = "2013",
month = "6",
language = "English",
volume = "37",
pages = "179--189",
journal = "Biochimica Clinica",
issn = "0393-0564",
publisher = "CLAS International",
number = "3",

}

TY - JOUR

T1 - Serum human epididymis protein 4 vs. carbohydrate antigen 125 for ovarian cancer diagnosis

T2 - A systematic review

AU - Ferraro, Simona

AU - Braga, Federica

AU - Lanzoni, Monica

AU - Boracchi, Patrizia

AU - Biganzoli, Elia Mario

AU - Panteghini, Mauro

PY - 2013/6

Y1 - 2013/6

N2 - Human epididymis protein 4 (HE4) measurements in serum have been proposed for improving the specificity of laboratory identification of ovarian cancer (OC). This study sought to critically revise the available literature on the comparison between the diagnostic accuracy of HE4 and carbohydrate antigen 125 (CA-125) to provide evidence of HE4 additional clinical value. Literature search was undertaken on electronic databases and references from retrieved articles, and articles analyzed according to predefined criteria. Meta-analyses for HE4 and CA-125 biomarkers with odds ratio (OR), diagnostic sensitivity, specificity, positive (LR+) and negative (LR-) likelihood ratios as effect sizes were performed. Sixteen articles were originally included in meta-analyses, but two for HE4 and one for CA-125 were eliminated as outliers. Furthermore, for HE4 a publication bias was detected. ORs for both HE4 (37.2, 95% CI: 19.0-72.7, adjusted for publication bias) and CA-125 (15.4, 95% CI: 10.4-22.8) were significant, although in a heterogeneous set of studies (P

AB - Human epididymis protein 4 (HE4) measurements in serum have been proposed for improving the specificity of laboratory identification of ovarian cancer (OC). This study sought to critically revise the available literature on the comparison between the diagnostic accuracy of HE4 and carbohydrate antigen 125 (CA-125) to provide evidence of HE4 additional clinical value. Literature search was undertaken on electronic databases and references from retrieved articles, and articles analyzed according to predefined criteria. Meta-analyses for HE4 and CA-125 biomarkers with odds ratio (OR), diagnostic sensitivity, specificity, positive (LR+) and negative (LR-) likelihood ratios as effect sizes were performed. Sixteen articles were originally included in meta-analyses, but two for HE4 and one for CA-125 were eliminated as outliers. Furthermore, for HE4 a publication bias was detected. ORs for both HE4 (37.2, 95% CI: 19.0-72.7, adjusted for publication bias) and CA-125 (15.4, 95% CI: 10.4-22.8) were significant, although in a heterogeneous set of studies (P

UR - http://www.scopus.com/inward/record.url?scp=84880870439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880870439&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84880870439

VL - 37

SP - 179

EP - 189

JO - Biochimica Clinica

JF - Biochimica Clinica

SN - 0393-0564

IS - 3

ER -